Results 41 to 50 of about 493,161 (298)
Clinical correlates of circulating cell-free DNA tumor fraction.
PLoS ONE, 2021 BackgroundOncology applications of cell-free DNA analysis are often limited by the amount of circulating tumor DNA and the fraction of cell-free DNA derived from tumor cells in a blood sample.
Joerg Bredno +4 more
doaj +1 more source
Research progress on circulating tumor cells of hepatocellular carcinoma
Journal of Interventional Medicine, 2021 Circulating tumor cells (CTCs) are the cells released from the primary tumor and found in the peripheral blood, which can colonize and develop at a distance through blood circulation. At present, the commonly used separation and detection methods of CTCs
Chenyu Wan, Bing Zhou
doaj +1 more source
Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells [PDF]
, 2017 Purpose: Early detection is essential for treatment plans before onset of metastatic disease. Our purpose was to demonstrate feasibility to detect and monitor estrogen receptor 1 (ESR1) gene mutations at the single circulating tumor cell (CTC) level in ...
Austin, Laura +9 more
core +3 more sources
Distinct blood and visceral adipose tissue regulatory T cell and innate lymphocyte profiles characterize obesity and colorectal cancer [PDF]
, 2017 Visceral adipose tissue (VAT) is a main site where metabolic and immunologic processes interplay to regulate, at local and systemic level, the inflammatory status and immune response.
Barbara Varano +14 more
core +2 more sources
Frontiers in Digital Health, 2020 Improving cancer survival rates globally requires improvements in disease detection and monitoring, with the aim of improving early diagnosis and prediction of disease relapse. Traditional means of detecting and monitoring cancers rely largely on imaging
Mark R. Openshaw, Terri P. McVeigh
doaj +1 more source
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]
, 2019 Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence +2 more
core +2 more sources
Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma [PDF]
, 2018 Hemangiopericytoma (HPT) is a rare mesenchymal tumor of fibroblastic type and for its rarity is poorly studied. The most common sites of metastatic disease in patients with intracranial HPT are the bone, liver, and lung, suggestive for an hematogenous ...
Carpino, Guido +9 more
core +3 more sources
Evaluation of pre-analytical factors affecting plasma DNA analysis. [PDF]
, 2018 Pre-analytical factors can significantly affect circulating cell-free DNA (cfDNA) analysis. However, there are few robust methods to rapidly assess sample quality and the impact of pre-analytical processing. To address this gap and to evaluate effects of
Berens, Michael E +15 more
core +1 more source
Frontiers in OncologyBackgroundThe heterogeneous and complex genetic landscape of NSCLC impacts the clinical outcomes of patients who will eventually develop resistance to osimertinib.
Aliki Ntzifa +5 more
doaj +1 more source
Opportunities and challenges of liquid biopsy in liver cancer
Clinical Surgical Oncology, 2023 Liver cancer is currently the third leading cause of cancer-related mortality worldwide. Due to late diagnosis and difficulty in monitoring, there is a pressing need for early detection and recurrence monitoring in patients with liver cancer.
Yu-Chen Zhong +5 more
doaj +1 more source